Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitochondrial cytochrome bc₁ complex (complex III) is an intrinsic membrane protein dimer consisting of several subunits, most notably cytochrome b, cytochrome c₁, and the Rieske iron-sulfur protein. It catalyzes the oxidation of ubiquinol and the reduction of cytochrome c via the Q-cycle mechanism, generating a proton gradient essential for mitochondrial ATP production. Dysfunction in this complex can result in mitochondrial myopathies and contributes to increased production of reactive oxygen species, which are implicated in aging and various diseases. The complex is a key therapeutic target, with several drugs and research inhibitors acting by binding its quinone sites and disrupting electron transfer. Structural studies reveal it functions as a dimer, with coordinated binding and electron transfer across subunits.
Inhibition of electron transport by blocking quinone (ubiquinol) binding sites (Qo/Qi sites) or interfering with electron transfer; Disruption of the proton gradient, leading to impaired ATP synthesis
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial cytochrome bc₁ complex (Cytochrome bc₁ complex).